Literature DB >> 7128637

Hemodynamic effects of sodium nitroprusside in patients with ventricular septal defect.

R Subramanyam, R Tandon, S Shrivastava.   

Abstract

During routine cardiac catheterization of ten patients with ventricular septal defect, the hemodynamic parameters were measured in the resting state and during sodium nitroprusside infusion at an average rate of 8 micrograms/kg/min. Two distinct hemodynamic groups could be identified. Group I characterised by elevated left ventricular filling pressure showed a consistently favourable response to sodium nitroprusside infusion with a decrease in the left ventricular filling pressure, the pulmonary arterial pressures and the left to right shunt. The favourable effect was most pronounced in patients who had pulmonary arterial hypertension in addition to elevated left ventricular filling pressures. Group II patients characterised by normal left ventricular filling pressures showed a variable response to sodium nitroprusside administration. The left ventricular end-diastolic pressure fell or was unaltered. The pulmonary arterial pressures and pulmonary vascular resistance fell in those with pulmonary arterial hypertension. Patients without pulmonary arterial hypertension showed an increase in the magnitude of left to right shunt. On the basis of our data, we feel that vasodilator drugs have a specific role in the management of congestive heart failure secondary to large left to right shunts. The present study strongly indicates the need for further investigations utilizing orally effective vasodilators in patients with congestive heart failure due to left to right shunts.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7128637     DOI: 10.1007/bf00442503

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  13 in total

1.  Afterload reduction in the management of postinfarction ventricular septal defect.

Authors:  P L Tecklenberg; J Fitzgerald; B I Allaire; E L Alderman; D C Harrison
Journal:  Am J Cardiol       Date:  1976-12       Impact factor: 2.778

2.  Reduction of pulmonary hypertension by nitroprusside.

Authors:  E Knapp; R Gmeiner
Journal:  Int J Clin Pharmacol Biopharm       Date:  1977-02

3.  Phentolamine for vasodilator treatment of severe heart-failure.

Authors:  P A Majid; B Sharma; S H Taylor
Journal:  Lancet       Date:  1971-10-02       Impact factor: 79.321

4.  Treatment of refractory heart failure with infusion of nitroprusside.

Authors:  N H Guiha; J N Cohn; E Mikulic; J A Franciosa; C J Limas
Journal:  N Engl J Med       Date:  1974-09-19       Impact factor: 91.245

5.  Hemodynamic and metabolic responses to vasodilator therapy in acute myocardial infarction.

Authors:  K Chatterjee; W W Parmley; W Ganz; J Forrester; P Walinsky; C Crexells; H J Swan
Journal:  Circulation       Date:  1973-12       Impact factor: 29.690

6.  Hemodynamic effects of trinitroglycerin in aortic and mitral valve disease.

Authors:  R S Kasliwal; S C Manchanda; M L Bhatia; H S Wasir
Journal:  Indian Heart J       Date:  1980 Jan-Feb

7.  Clinical use of sodium nitroprusside in chronic ischemic heart disease. Effects on peripheral vascular resistance and venous tone and on ventricular volume, pump and mechanical performance.

Authors:  R R Miller; L A Vismara; R Zelis; E A Amsterdam; D T Mason
Journal:  Circulation       Date:  1975-02       Impact factor: 29.690

8.  Effects of nitroprusside and dopamine on pulmonary arterial vasculature in children after cardiac surgery.

Authors:  L W Stephenson; L H Edmunds; R Raphaely; D F Morrison; W S Hoffman; L J Rubis
Journal:  Circulation       Date:  1979-08       Impact factor: 29.690

9.  Haemodynamic effects of sodium nitroprusside in 21 subjects with congestive heart failure.

Authors:  S A Lukes; C A Romero; L Resnekov
Journal:  Br Heart J       Date:  1979-02

10.  Oral hydralazine therapy for primary pulmonary hypertension.

Authors:  L J Rubin; R H Peter
Journal:  N Engl J Med       Date:  1980-01-10       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.